XML 50 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Revenues (Tables)

3 Months Ended

Mar. 31, 2014

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three months ended March 31, 2014 and 2013:

	Three months ended March 31,
	2014				2013
Products:
Acetadote	$	2,721,086			$	7,251,995
Omeclamox-Pak	1,139,421				—
Kristalose	3,376,057				2,117,250
Vaprisol	298,332				—
Caldolor	502,398				410,424
Other	55,950				478,463
Total net revenues	$	8,093,244			$	10,258,132

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration